#ECO 2026

19 stories

The European Congress on Obesity 2026 runs May 12–15 in Istanbul and is the next major obesity-medicine readout cycle after the Q1 earnings season. Novo Nordisk leads the abstract count with 52 presentations spanning the full STEP UP data for Wegovy 7.2 mg (following the April 7 launch and Q1 contribution), CagriSema higher-dose Phase 3 plans (after the February 2026 head-to-head loss against tirzepatide and the May 6 Q1 disclosure that the single-chamber co-formulation was discontinued), Wegovy pill efficacy and tolerability, and women's-obesity, perimenopause, and migraine subgroups.

A 21-expert global panel of obesity and cancer specialists is also expected to formally present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists for prevention of obesity-related cancers — building on SELECT cardiovascular benefit data, real-world dementia-incidence reductions, and the Lancet Psychiatry mental-health cohort. AstraZeneca's eleglipron full Phase 2b data from VISTA and SOLSTICE is on the ADA 2026 schedule the following month.

Stories here cover ECO readouts and the surrounding obesity-pharmacology calendar. See #wegovy, #cagrisema, and #novo-nordisk.

Industry April 29, 2026 · View digest

Novo Nordisk Previews 52 ECO 2026 Abstracts on CagriSema, Higher-Dose Wegovy, and Women's Obesity Data Ahead of Istanbul Congress

Novo Nordisk announced April 28 that it will present 52 abstracts at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), including new data from the REDEFINE 1 trial of CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg): body composition and muscle strength, achievement of BMI/waist-to-height ratio targets, and cardiovascular risk reduction. Additional presentations will cover higher-dose Wegovy (semaglutide 7.2 mg), the Wegovy pill (oral semaglutide 25 mg) from OASIS 4 and ORION trials, and obesity treatment outcomes in women. The disclosure sets up a significant amylin/GLP-1 combination data event exactly as Zealand and Roche's amylin-only petrelintide moves into Phase 3.